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Association Between Maternal Folic Acid Supplementation and
Congenital Heart Defects in Offspring in Birth Cohorts From Denmark
and Norway
Nina Øyen, MD, MPH, DrMed; Sjurdur F. Olsen, MD, PhD, DrMed; Saima Basit, MSc; Elisabeth Leirgul, MD, PhD; Marin Strøm, PhD;
Lisbeth Carstensen, PhD; Charlotta Granstr€om, MSc; Grethe S. Tell, MPH, PhD; Per Magnus, MD, DrMed; Stein E. Vollset, MD, DrPH;
Jan Wohlfahrt, MSc, DrMedSc; Mads Melbye, MD, DrMedSc
Background-—Evidence linking individual-level maternal folic acid supplementation to offspring risk of congenital heart defects is
lacking. We investigated whether folic acid supplementation in early pregnancy reduces offspring risk of heart defects in 2 large
birth cohort studies.
Methods and Results-—Women recruited in early pregnancy within the DNBC (Danish National Birth Cohort), 1996–2003, and
MoBa (Norwegian Mother and Child Cohort Study), 2000–2009, were followed until delivery. Information on periconceptional
intake of folic acid and other supplements was linked with information on heart defects from national registers. Among 197 123
births, we identiﬁed 2247 individuals with heart defects (114/10 000). Periconceptional (4 weeks before through 8 weeks after
conception) use of folic acid plus other supplements (54.8%), folic acid only (12.2%), and non–folic acid supplements (5.0%) were
compared with no supplement use (28.0%); the adjusted relative risks of heart defects were 0.99 (95% CI, 0.80–1.22), 1.08 (95%
CI, 0.93–1.25), and 1.07 (95% CI, 0.97–1.19), respectively. For initiation of folic acid in the preconception period weeks 4 to 1
(33.7%) and the postconception periods 0 to 4 weeks (15.5%), 5 to 8 weeks (17.8%), and 9 to 12 weeks (4.6%), compared with no
or late folic acid intake (29.1%), relative risks of heart defect were 1.11 (95% CI, 1.00–1.25), 1.09 (95% CI, 0.95–1.25), 0.98 (95%
CI, 0.86–1.12), and 0.97 (95% CI, 0.78–1.20), respectively. Relative risks of severe defects, conotruncal defects, and septal defects
showed similar results.
Conclusions-—Folic acid was not associated with offspring risk of heart defects, including severe defects, conotruncal defects, or
septal defects. ( J Am Heart Assoc. 2019;8:e011615. DOI: 10.1161/JAHA.118.011615.)
Key Words: congenital cardiac defect • folate • MoBa (Norwegian Mother and Child Cohort Study) • pregnancy • prospective
cohort study
C ongenital heart defects are the most common birthdefects worldwide, but their etiology is largely
unknown.1,2 Gene defects contribute to the occurrence of
heart malformations,3 but most heart defects occur in
isolation in a family.4 Consequently, a large proportion of
heart defects presumably arise in susceptible individuals who
carry low-penetrance genes or gene combinations, possibly in
interaction with maternal or intrauterine factors. Although it is
well established that maternal intake of folic acid around the
time of conception reduces the risk of neural tube defect in
offspring,5,6 its association with reduced risk of congenital
heart defects is only suggestive.7,8
Although the precise role of folic acid supplementation on
cardiac morphogenesis remains unclear, folic acid may have a
role in the migration of the cardiac neural cells that contribute
to the development of the embryonic heart.9,10 It is important
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to corroborate this hypothesis with evidence from clinical and
population-based cohort studies with prospectively collected
information on individual-level maternal folic acid intake. To
date, this hypothesis is supported by results from 1 random-
ized trial of high-dose folic acid supplementation,11 2 case–
control studies7,8 and 1 hospital-based case–control study.12
However, no signiﬁcant associations were found in 4 other
case–control studies of birth defects including cardiac
defects, in studies of cardiac outﬂow defects,13–16 or in a
nationwide cohort study of supplement use in pregnancy and
offspring risk of heart defect.17 The inconsistencies among
these studies may be related to design differences, recall bias
of retrospectively collected exposure data in case–control
studies, or less accurate information on dose or timing of folic
acid supplementation in pregnancy; therefore, the evidence
for a preventive effect of folic acid supplementation on heart
defects is still inconclusive.
Knowledge of whether folic acid supplementation may
reduce the risk of heart defects is important in strategies for
the prevention of congenital malformations.18 Heart defects
account for a third of infant deaths caused by malformations
in industrialized countries,19 and severe heart defects require
costly and complex surgical intervention.20 To date, Denmark
and Norway have a policy of no food fortiﬁcation with folic
acid.
We have utilized 2 unique large prospective birth cohorts,
the DNBC (Danish National Birth Cohort)21 and MoBa
(Norwegian Mother and Child Cohort Study)22 to investigate
whether periconceptional folic acid supplementation mea-
sured as individual-level information of folic acid exposure
from up to 4 weeks before through 8 weeks after conception,
including the timing of folic acid initiation, reduces the risk of
congenital heart defects.
Methods
We can make tabulated data and analytical methods available
to other researchers on reasonable request sent to the
corresponding author.
Independent Data Access and Analyses
All authors had the ability to query any aspect of the data
either directly or through independent analysis. Authors N.Ø.,
S.B., and J.W. had full access to all data in the study and take
responsibility for its integrity and the data analysis.
Birth Cohorts
DNBC, 1996–2003
More than 100 000 Danish women in early pregnancy were
recruited to the DNBC.21 By linkage, all births were updated
with information on heart defects in their children, retrieved
from the National Patient Register (NPR) and the Causes of
Death Register, classiﬁed into cardiac phenotypes as pub-
lished previously.4,23 In addition, information on chromosomal
aberrations from the Danish Cytogenetic Central Register,
University of Aarhus, and familial heart defect cases from the
Danish Familial Relational Database were included. The NPR
contains information on in-patient diagnoses assigned since
1977 and outpatient diagnoses from 1995 onward. Diagnoses
of heart defects in the NPR have been validated against
clinical records.24 The Causes of Death Register contains
death certiﬁcate information, including underlying cause of
death and up to 3 contributing causes of death since 1970,
with high validity for infant death causes.25 The Danish
Cytogenetic Central Register was established in 1968 and
contains reports on all pre- and postnatal chromosomal
analyses performed in Denmark since 1970 and 1960,
respectively.
MoBa, 2000–2009
By June 2009, >100 000 pregnant women were included in
MoBa.22 We used the MoBa analytic data ﬁle version 7, linked
with information from the Medical Birth Registry of Norway. All
births in MoBa were updated with information on heart defect
Clinical Perspective
What Is New?
• In 2 independent prospective birth cohorts of almost
200 000 births, we identiﬁed 2247 children with congenital
heart defects. Our results do not support the hypothesis
that maternal intake of supplements containing folic acid
before or after conception reduces the risk of congenital
heart defects in offspring.
• Our null association between maternal folic acid supple-
mentation and offspring congenital heart defects was
consistent across various deﬁnitions of folic acid exposure
and types of cardiac defects.
What Are the Clinical Implications?
• Although most likely not harmful, the effect of maternal folic
acid supplementation with respect to preventing cardiac
birth defects may be questioned, at least in regions with
sufﬁcient intake of dietary folate.
• Our ﬁnding of no association between individual-level
maternal folic acid supplementation and offspring heart
defect is in contrast to time trend studies claiming a causal
relationship between folic acid and heart defects when
comparing trends of birth prevalence of heart defects before
and after folic acid fortiﬁcation of staple food.
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from a national project database on heart defects, Congenital
Heart Defects in Norway, Cardiovascular Disease in Norway
Project (https://cvdnor.w.uib.no/), in which individuals with
heart defects were ascertained from 4 data sources: the
Medical Birth Registry of Norway, the hospitals’ patient
administrative systems, Oslo University Hospital’s clinical
database for children with heart disease, and the Causes of
Death Registry.26 Individuals with heart defects had been
assigned speciﬁc cardiac phenotypes before linkage with
MoBa. Information on chromosomal aberration and familial
heart defect was ascertained from the Medical Birth Registry.
Dietary Supplement: Assessment of Folic Acid
Exposure
In the DNBC, information on folic acid brand names, dosage,
and frequency of use was collected at enrollment covering the
period from 4 weeks before the last menstrual period until
enrollment (around the 12th gestational week). At enrollment
the women answered a questionnaire including information on
supplement use. This recruitment form had 2 formats during
the study period: initially a format with a ﬂoating time window
and then, halfway through the study period, a format with a
ﬁxed time window (each week speciﬁed from gestational
week 4 to week 14). Information from the ﬁrst recruitment
form was manually set to the same format as the second
recruitment form.27 In MoBa, the women answered a
questionnaire including information on folic acid supplement
use and intake of speciﬁc nutrients from 3 months before
pregnancy and throughout pregnancy until enrollment (18th
gestational week). More detailed information on exposure
matrixes in both cohorts has been published.28–30 Data have
also been used to evaluate health campaigns for the intake of
folic acid during pregnancy.29 Self-reported folic acid intake
has been validated and found to mirror biological levels of
folate in erythrocytes31 and in plasma.32 Therefore, use of
folic acid is one of the most well-deﬁned exposures so far
characterized collaboratively between the 2 cohorts with the
original objective of studying its inﬂuence on neural tube
defects.
The embryonic heart forms from the second through the
eighth weeks after conception.33 Therefore, the presumed
window of susceptibility from insufﬁcient maternal folate
regarding embryonic heart development was deﬁned as
4 weeks before through 8 weeks after conception. Exposure
information of maternal folic acid supplement use was
classiﬁed by 2 approaches (supplement type and timing), as
suggested by Roth and colleagues.34,35 First, we assessed any
supplement use 4 weeks before through 8 weeks after
conception for 4 mutually exclusive exposure categories: folic
acid (0.4 mg) plus other micronutrient supplements, only folic
acid, other non–folic acid supplements, and no supplements
(as the reference). Next, we evaluated initiation of any folic
acid intake (folic acid plus other supplements were combined
with folic acid only) for 4 time windows: 4 weeks before
conception, 4 weeks after conception, 5 to 8 weeks after
conception, and 9 to 12 weeks (9–11 weeks in Denmark)
after conception, with no folic acid supplementation (no
supplements was combined with non–folic acid supplements)
in the period 4 weeks before to 12 weeks (11 weeks in
Denmark) after conception (as the reference).
Case Ascertainment and Classiﬁcation of
Congenital Heart Defects
In both birth cohorts, infants with International Classiﬁcation
of Diseases, 10th Revision (ICD-10) codes for heart defects
were classiﬁed into cardiac phenotypes in a hierarchical
system23,26,36: heterotaxia, conotruncal defects, atrioventric-
ular septal defects, anomalous pulmonary venous return, left
ventricle outﬂow tract obstruction, right ventricle outﬂow tract
obstruction, isolated septal defects (ventricular septal
defects, atrial septal defects registered after 6 weeks, and
ventricular plus atrial septal defects), complex defects, patent
ductus arteriosus registered after 6 weeks or with surgical
correction in preterm live births (gestational age <37 weeks)
or live births at term (gestational age ≥37 weeks), other
speciﬁed heart defects, unspeciﬁed heart defects (Table S1).
In tables, we report relative risk estimates for any type of
heart defect (not counting patent ductus arteriosus in preterm
births), severe heart defects (heterotaxia, conotruncal
defects, atrioventricular septal defects, anomalous pulmonary
venous return, left or right ventricle outﬂow tract obstruction,
complex defects combined), conotruncal defects, and septal
defects (ventricular septal defects, atrial septal defects
registered after 6 weeks, and ventricular plus atrial septal
defects).
Potential Confounders and Stratiﬁcation
Variables
We decided a priori on the following potential confounders
(variables associated with maternal folic acid supplement use
and most likely also with the risk of heart defect in offspring)
for the association between maternal folic acid supplemen-
tation and offspring heart defect risk: year of birth and birth
order, maternal age, prepregnancy body mass index (kg/m2),
and epilepsy (or intake of folic acid antagonists for maternal
epilepsy). In addition, we also considered maternal socioeco-
nomic status and education, pregestational diabetes mellitus,
smoking, and alcohol consumption as possible confounders.
We did not, however, include these factors in the ﬁnal model
because they were either associated only with the exposure
(maternal education, smoking, alcohol consumption) or only
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with heart defects in the offspring (pregestational diabetes
mellitus). We also explored the main effects when restricting
the analyses by information on live births, singletons, mother
without heart defect, or planned pregnancy. Individuals with
missing data for the covariates among all births (10 352 of
197 213, 5.5%) and births with cardiac defect (117 of 2247,
5.2%) were not included in the multivariable regression
analyses.
Study Cohort and Statistical Analysis
The 2 study cohorts consisted of live births, and MoBa also
included stillbirths and pregnancy termination for fetal
abnormalities. We excluded births with chromosomal aberra-
tions (353 in DNBC and 140 births in MoBa). The association
between maternal folic acid intake and the risk of heart defect
was calculated as risk ratios (RRs) comparing offspring risk of
heart defect among those exposed and not exposed to
supplementation. The RRs were estimated with 95% CIs in log-
linear binominal regression analyses with adjustment for the a
priori confounders in the separate analyses of the Danish and
Norwegian cohorts, and then with adjustment for interactions
between country and the a priori country-speciﬁc confounders
when combining the 2 cohorts.
Study Size and Power Calculation
A priori, we estimated that we would be able to detect a
reduced risk of heart defect (all types combined) and
conotruncal defects among infants exposed to folic acid
supplementation of at least 16% and 41%, respectively,
relative to unexposed infants. Estimates were based on 80%
power and a 5% signiﬁcance level, the Danish prevalence of
heart defects without chromosomal aberrations in 93 per
10 000 and in 12 per 10 000 for conotruncal defects,23 and a
mean prevalence of folic acid supplementation of 23%
(Denmark 13.5%37 and Norway 32.0%28).
Ethics
We have approval from the DNBC’s steering committee (ref.
no 2010-05; May 4, 2010), a general approval granted to
the Statens Serum Institut from the Danish Data Protection
Agency (J.nr.2008-54-0472; September 12, 2008), and an
approval from the steering board of the Danish Cytogenetic
Central Register. We also have approval from MoBa’s
steering committee (PD757; 09/3237; February 5, 2010);
the Regional Committee for Medical and Health Research
Ethics, South-East Norway (2012/796); and the steering
committee of the Cardiovascular Disease in Norway project.
Written informed consent was obtained from all participat-
ing women.
Results
Denmark: DNBC
In the study cohort from Denmark of 94 228 births without
chromosomal aberrations, we present information on mothers’
periconceptional intake of supplements (Table 1). In the
period 1996–2003, maternal intake of folic acid plus other
supplements not containing folic acid was reported in 59.0% of
the births, intake of only folic acid was reported in 4.1%, use of
other non–folic acid supplements was reported in 3.7%, and no
maternal supplement intake was reported in 33.2%.
Norway: MoBa
The study cohort from Norway consisted of 102 985 births
without chromosomal aberrations (Table 2). In the period
1999–2009, the mother reported intake of folic acid plus
other supplements in 50.3% of the births, folic acid only in
19.0%, other supplements without folic acid in 6.2%, and no
supplement intake in 24.5%.
Maternal use of folic acid or other supplements is shown
for maternal and birth characteristics in both cohorts
(Tables 1 and 2).
Cardiac Defects and Birth Prevalence in the
Danish and Norwegian Birth Cohorts
Country-speciﬁc numbers of heart defects and birth prevalence
are presented in Table 3. The 2 birth cohorts were combined,
and among 197 213 births, there were 2247 infants with any
type of heart defect, not counting patent ductus arteriosus
among preterm births (birth prevalence 114 per 10 000 births).
There were 583 infants with severe heart defect (30 per
10 000), of which 201 had conotruncal defect (10 per 10 000
births), and 1191 infants had septal defect (60 per 10 000).
Folic Acid Supplementation and Risk of
Congenital Heart Defects in Denmark and
Norway
Excluding 5.2% with missing values, the combined cohort
consisted of 186 861 births. In the period from 4 weeks
before through 8 weeks after conception, 54.8% of the
mothers used folic acid plus other types of non–folic acid
supplements, 12.2% took only folic acid supplements, 5.0%
used non–folic acid supplements, and 28.0% did not use any
supplements (Table 4). The adjusted RRs for any type of heart
defect in offspring were 0.99 (95% CI, 0.80–1.22) for maternal
intake of folic acid plus other supplements, 1.08 (95% CI,
0.93–1.25) for only folic acid supplements, and 1.07 (95% CI,
0.97–1.19) for non–folic acid supplements, compared with no
supplement use. RR estimates were similarly nonsigniﬁcant
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Table 1. Maternal Characteristics by Maternal Use of Supplements From 4 Weeks Before to 8 Weeks After Conception Among
94 228 Births Without Chromosomal Aberrations in the DNBC, Denmark, 1996–2003
Characteristics
Total
N=94 228
(100%)
No
Supplements
n=31 322
(33.2%)
Other Supplements
No Folic Acid
n=3453
(3.7%)
Folic Acid
Only
n=3889 (4.1%)
Folic Acid Plus Other
Supplements
n=55 564
(59.0%)
P Value, No
Folic Acid vs
Folic Acid
Use*
Year of birth†
1996 139 (0.15) 69 (49.6) 12 (8.6) 0 (0) 58 (41.7) <0.0001
1997 750 (0.80) 346 (46.1) 43 (5.7) 9 (1.2) 352 (46.9)
1998 12 077 (12.8) 4442 (36.8) 767 (6.4) 260 (2.2) 6608 (54.7)
1999 18 548 (19.7) 7188 (38.8) 924 (5.0) 459 (2.5) 9977 (53.8)
2000 20 540 (21.8) 7230 (35.2) 764 (3.7) 823 (4.0) 11 723 (57.1)
2001 20 135 (21.4) 6254 (31.1) 555 (2.8) 933 (4.6) 12 393 (61.6)
2002 18 084 (19.2) 4681 (25.9) 324 (1.8) 1123 (6.2) 11 956 (66.1)
2003 3955 (4.2) 1112 (28.1) 64 (1.6) 282 (7.1) 2497 (63.1)
Maternal age, y†
≤24 8996 (9.55) 3871 (43.0) 343 (3.8) 287 (3.2) 4495 (50.0) <0.0001
25–29 35 891 (38.1) 11 515 (32.1) 1187 (3.3) 1488 (4.2) 21 701 (60.5)
30–34 35 117 (37.3) 11 277 (32.1) 1279 (3.6) 1479 (4.2) 21 082 (60.0)
≥35 14 113 (15.0) 4628 (32.8) 640 (4.5) 627 (4.4) 8218 (58.2)
Missing 111 (0.12) 31 (27.9) 4 (3.6) 8 (7.2) 68 (61.3)
Birth order
First 41 698 (44.3) 12 255 (29.4) 1374 (3.3) 2049 (4.9) 26 020 (62.4) <0.0001
Second 32 425 (34.4) 10 829 (33.4) 1226 (3.8) 1188 (3.7) 19 182 (59.2)
Third 11 435 (12.1) 4542 (39.7) 497 (4.4) 384 (3.4) 6012 (52.6)
Fourth or higher 2649 (2.8) 1171 (44.2) 146 (5.5) 76 (2.9) 1256 (47.4)
Missing 6021 (6.4) 2525 (41.9) 210 (3.5) 192 (3.2) 3094 (51.4)
Maternal body mass index before pregnancy (kg/m2)
<20 14 414 (15.3) 4516 (31.3) 591 (4.1) 596 (4.1) 8711 (60.4) <0.0001
20–24 48 238 (51.2) 15 178 (31.5) 1843 (3.8) 2054 (4.3) 29 163 (60.5)
25–29 16 886 (17.9) 5867 (34.7) 544 (3.2) 682 (4.0) 9793 (58.0)
30–34 5255 (5.6) 1904 (36.2) 160 (3.0) 223 (4.2) 2968 (56.5)
≥35 1993 (2.1) 748 (37.5) 41 (2.1) 94 (4.7) 1110 (56.0)
Missing data 7442 (7.9) 3109 (41.8) 274 (3.7) 240 (3.2) 3819 (51.3)
Maternal heart defect
Yes 445 (0.47) 136 (30.6) 12 (2.7) 13 (2.9) 284 (63.8) 0.14
No 93 783 (99.5) 31 186 (33.3) 3441 (3.7) 3876 (4.1) 55 280 (58.9)
Epilepsy before pregnancy
Yes 351 (0.37) 82 (23.4) 13 (3.7) 50 (14.2) 206 (58.7) <0.0001
No 93 877 (99.6) 31 240 (33.3) 3440 (3.7) 3839 (4.1) 55 358 (59.0)
Pregestational diabetes mellitus
Yes 285 (0.3) 96 (33.7) 12 (4.2) 9 (3.2) 168 (58.9) 0.83
No 93 943 (99.7) 31 226 (33.2) 3441 (3.7) 3880 (4.1) 55 396 (59.0)
Maternal smoking in pregnancy
Nonsmokers 67 769 (71.9) 20 869 (30.8) 2440 (3.6) 3032 (4.5) 41 428 (61.1) <0.0001
Continued
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for conotruncal defects, severe heart defects, and septal
defects for any combination of intake of folic acid and non–
folic acid supplementation.
We next analyzed initiation of any folic acid supplementa-
tion within the period from 4 weeks before to 12 weeks after
conception (Table 4). Among the 186 861 births, 33.7% of
the mothers started folic acid supplementation during weeks
4 to 1, 15.3% started during weeks 0 to 4, 17.6% started
during weeks 5 to 8, and 4.6% started during weeks 9 to 12,
whereas 29.1% did not take folic acid supplementation or
started to take folic acid supplementation after week 12. The
adjusted RRs of any heart defect in offspring were 1.11 (95%
CI, 1.00–1.25), 1.09 (95% CI, 0.95–1.25), 0.98 (95% CI, 0.86–
1.12), and 0.97 (95% CI, 0.78–1.20) for maternal folic acid
intake in weeks 4 to 1, 0 to 4, 5 to 8, and 9 to 12,
respectively, compared with the reference group with no or
late folic acid intake. RR estimates were similarly nonsignif-
icant for severe heart defects, conotruncal defects, and septal
defects for any timing of folic acid use compared with no folic
acid use.
Numbers and relative risks of offspring heart defect for
maternal intake of folic acid and other non–folic acid
supplements were estimated separately for Denmark and
Norway (Tables S2 and S3). In each country, the relative risk
of heart defects in offspring was nonsigniﬁcant when
comparing folic acid with no folic acid in early pregnancy.
In Table S4, adjusted RRs in the combined cohort showed
similar null ﬁndings for the association between folic acid and any
heart defectorconotruncal defectsusing theﬁnalmodel,model2
with further adjustment for maternal education, or model 3 with
Table 1. Continued
Characteristics
Total
N=94 228
(100%)
No
Supplements
n=31 322
(33.2%)
Other Supplements
No Folic Acid
n=3453
(3.7%)
Folic Acid
Only
n=3889 (4.1%)
Folic Acid Plus Other
Supplements
n=55 564
(59.0%)
P Value, No
Folic Acid vs
Folic Acid
Use*
Sometimes 11 391 (12.1) 3931 (34.5) 421 (3.7) 444 (3.9) 6595 (57.9)
Daily <15 cigarettes 10 662 (11.3) 4403 (41.3) 406 (3.8) 329 (3.1) 5524 (51.8)
Daily ≥15 cigarettes 2088 (2.2) 1033 (49.5) 99 (4.7) 36 (1.7) 920 (44.2)
Missing data 2318 (2.5) 1086 (46.9) 87 (3.8) 48 (2.1) 1097 (47.3)
Prepregnancy alcohol intake
Yes 51 754 (54.9) 16 786 (32.4) 1976 (3.8) 2199 (4.3) 30 793 (59.5) 0.0004
No 40 152 (42.6) 13 448 (33.5) 1389 (3.5) 1642 (4.1) 23 673 (59.0)
Missing data 2322 (2.46) 1088 (46.9) 88 (3.8) 48 (2.1) 1098 (47.3)
Maternal socioeconomic status
High 7944 (8.4) 2202 (27.7) 280 (3.5) 503 (6.3) 4959 (62.4) <0.0001
Medium 23 717 (25.2) 6758 (28.5) 837 (3.5) 1088 (4.6) 15 034 (63.4)
Skilled 15 850 (16.8) 5138 (32.4) 579 (3.7) 673 (4.2) 9460 (59.7)
Student 9575 (10.2) 3048 (31.8) 328 (3.4) 444 (4.6) 5755 (60.1)
Unskilled 18 628 (19.8) 7016 (37.7) 696 (3.7) 613 (3.3) 10 303 (55.3)
Unemployed 9513 (10.1) 3616 (38.0) 403 (4.2) 287 (3.0) 5207 (54.7)
Missing data 9001 (9.6) 3544 (39.4) 330 (3.7) 281 (3.1) 4846 (53.8)
Planned pregnancy
Yes 78 243 (83.0) 24 318 (31.1) 2772 (3.5) 3453 (4.4) 47 700 (61.0) <0.0001
No 9960 (10.6) 4470 (44.9) 471 (4.7) 245 (2.5) 4774 (47.9)
Missing data 6025 (6.4) 2534 (42.1) 210 (3.5) 191 (3.2) 3090 (51.3)
Plurality†
Single 90 180 (95.7) 30 261 (33.6) 3318 (3.7) 3716 (4.1) 52 885 (58.6) <0.0001
Twins/triplets 4048 (4.3) 1061 (26.2) 135 (3.3) 173 (4.3) 2679 (66.2)
Data are shown as n (%). DNBC indicates Danish National Birth Cohort.
*No folic acid use (no/other supplements, no folic acid) vs folic acid use (folic acid only/folic acid plus other supplements) 4 weeks before to 8 weeks after gestation (combining 4 to 0,
0–4, and 5–8 weeks).
†Data from Medical Birth Registry.
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Table 2. Maternal Characteristics by Maternal Use of Supplements From 4 Weeks Before to 8 Weeks After Conception Among
102 985 Births Without Chromosomal Aberrations in MoBa, Norway, 1999–2009
Characteristics
Total
N=102 985
(100%)
No Supplements
n=25 229
(24.5%)
Other Supplements
No Folic Acid
n=6431
(6.24%)
Folic Acid
Only
n=19 555 (19.0%)
Folic Acid Plus Other
Supplements
n=51 770 (50.3%)
P Value, No
Folic Acid vs
Folic Acid use*
Year of birth†
1999 46 (0.04) 30 (65.2) 4 (8.7) 6 (13.0) 6 (13.0) <0.0001
2000 2010 (2.0) 1047 (52.1) 223 (11.1) 316 (15.7) 424 (21.1)
2001 3931 (3.8) 1890 (48.8) 443 (11.3) 609 (15.5) 989 (25.2)
2002 8293 (8.1) 3960 (47.8) 846 (10.2) 1321 (15.9) 2166 (26.1)
2003 12 142 (11.8) 4615 (38.0) 1133 (9.3) 2208 (18.2) 4186 (34.5)
2004 13 073 (12.7) 3282 (25.1) 845 (6.5) 2541 (19.4) 6405 (49.0)
2005 15 117 (14.7) 3181 (21.0) 785 (5.2) 3094 (20.5) 8057 (53.3)
2006 16 775 (16.3) 2872 (17.1) 867 (5.2) 3177 (18.9) 9859 (58.8)
2007 15 474 (15.0) 2265 (14.6) 661 (4.3) 3028 (19.6) 9520 (61.5)
2008 12 904 (12.5) 1695 (13.1) 514 (4.0) 2620 (20.3) 8075 (62.6)
2009 3220 (3.1) 392 (12.2) 110 (3.4) 635 (19.7) 2083 (64.7)
Maternal age, y†
≤24 11 301 (11.0) 3999 (35.4) 883 (7.8) 2011 (17.8) 4408 (39.0) <0.0001
25–29 33 730 (32.8) 7920 (23.5) 1846 (5.5) 6739 (20.0) 17 225 (51.1)
30–34 39 916 (38.8) 8881 (22.3) 2378 (6.0) 7772 (19.5) 20 885 (52.3)
≥35 18 038 (17.5) 4429 (24.6) 1324 (7.3) 3033 (16.8) 9252 (51.3)
Birth order†
First 46 367 (45.0) 9566 (20.6) 2723 (5.9) 8282 (17.9) 25 796 (55.6) <0.0001
Second 36 576 (35.5) 8936 (24.4) 2105 (5.8) 7616 (20.8) 17 919 (49.0)
Third or higher 20 042 (19.5) 6727 (33.6) 1603 (8.0) 3657 (18.3) 8055 (40.2)
Maternal body mass index before pregnancy (kg/m2)
<20 12 700 (12.3) 2953 (23.3) 875 (6.9) 2104 (16.6) 6768 (53.3) <0.0001
20–24 56 079 (54.5) 12 656 (22.6) 3592 (6.4) 10 450 (18.6) 29 381 (52.4)
25–29 21 735 (21.1) 5671 (26.1) 1273 (5.9) 4505 (20.7) 10 286 (47.3)
30–24 7067 (6.9) 2154 (30.5) 366 (5.2) 1442 (20.4) 3105 (43.9)
≥35 2608 (2.5) 784 (30.1) 132 (5.1) 553 (21.2) 1139 (43.7)
Missing data 2796 (2.7) 1011 (36.2) 193 (6.9) 501 (17.9) 1091 (39.0)
Maternal heart defect
Yes 640 (0.62) 160 (25.0) 48 (7.5) 103 (16.1) 329 (51.4) 0.20
No 102 345 (99.4) 25 069 (24.5) 6383 (6.2) 19 452 (19.0) 51 441 (50.3)
Epilepsy before pregnancy
Yes 687 (0.67) 160 (23.3) 28 (4.1) 140 (20.4) 359 (52.3) 0.08
No 102 298 (99.3) 25 069 (24.5) 6403 (6.3) 19 415 (19.0) 51 411 (50.3)
Prepregnancy diabetes mellitus§
Yes 698 (0.68) 172 (24.6) 40 (5.7) 123 (17.6) 363 (52.0) 0.70
No 102 287 (99.3) 25 057 (24.5) 6391 (6.25) 19 432 (19.0) 51 407 (50.2)
Smoking before pregnancy
Daily 18 598 (18.1) 6574 (35.4) 1318 (7.1) 3438 (18.5) 7268 (39.1) <0.0001
Continued
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the following covariates added to model 1: maternal diabetes
mellitus, maternal smoking before conception, and maternal
alcohol consumption 3 months before conception.
In sensitivity analyses, we restricted the combined cohort
to live births, singleton births, births to mothers who did not
have a heart defect, or births of a planned pregnancy, and we
estimated sets of RRs for offspring risk of any heart defect
(Table S5). The RRs showed no association between folic acid
and any heart defect regardless of various restrictions of the
birth cohort.
Discussion
In 2 independent national birth cohorts in Denmark and
Norway of almost 200 000 pregnancies with prospectively
collected information on folic acid supplement intake with
follow-up of all births, we identiﬁed 2247 births with
congenital heart defects in the offspring. We did not ﬁnd
support for the hypothesis that maternal periconceptional
supplementation containing folic acid would reduce the risk of
congenital heart defects. The ﬁndings were consistent using 2
exposure approaches, any intake of folic acid supple-
mentation during the period from 4 weeks before and
8 weeks after conception, and timing of such intake in the
periconceptional period. Speciﬁcally the risks of conotruncal
defects, severe heart defects, or septal defects were not
reduced by such supplementation.
Previous Findings From Studies of the
Association Between Folic Acid and Congenital
Heart Defects
There are studies comparing birth prevalence trends before and
after staple food folic acid fortiﬁcation,38,39 claiming a causal
relationship between folic acid and heart defect.38 However, a
prerequisite for discussion of causal inference are studies
Table 2. Continued
Characteristics
Total
N=102 985
(100%)
No Supplements
n=25 229
(24.5%)
Other Supplements
No Folic Acid
n=6431
(6.24%)
Folic Acid
Only
n=19 555 (19.0%)
Folic Acid Plus Other
Supplements
n=51 770 (50.3%)
P Value, No
Folic Acid vs
Folic Acid use*
Sometimes 10 309 (10.0) 2388 (23.2) 628 (6.1) 1917 (18.6) 5376 (52.2)
No 61 352 (59.6) 11 346 (18.5) 3315 (5.4) 11 929 (19.4) 34 762 (56.7)
Missing 12 726 (12.4) 4921 (38.7) 1170 (9.2) 2271 (17.9) 4364 (34.3)
Prepregnancy alcohol intakek
Yes 88 509 (85.9) 16 824 (20.4) 4635 (5.61) 16 027 (19.4) 45 149 (54.6) <0.0001
No 7167 (6.96) 1459 (34.0) 363 (8.46) 785 (18.3) 1686 (39.3)
Missing 7309 (7.10) 1878 (44.7) 419 (9.97) 702 (16.7) 1205 (28.7)
Maternal education, y
<12 20 535 (19.9) 7987 (38.9) 1648 (8.03) 3661 (17.8) 7239 (35.3) <0.0001
12 14 458 (14.0) 4393 (30.4) 1081 (7.48) 2717 (18.8) 6267 (43.4)
13–16 39 916 (38.8) 8021 (20.1) 2229 (5.58) 8071 (20.2) 21 595 (54.1)
≥17 22 816 (22.2) 3337 (14.6) 1116 (4.89) 4166 (18.3) 14 197 (62.2)
Missing data 5260 (5.11) 1491 (28.4) 357 (6.79) 940 (17.9) 2472 (47.0)
Planned pregnancy
Yes 82 078 (79.7) 18 144 (22.1) 4664 (5.68) 16 377 (20.0) 42 893 (52.3) <0.0001
No 19 673 (19.1) 6658 (33.8) 1672 (8.50) 2997 (15.2) 8346 (42.4)
Missing data 1234 (1.20) 427 (34.6) 95 (7.70) 181 (14.7) 531 (43.0)
Plurality†
Single 99 320 (96.4) 24 450 (24.6) 6226 (6.3) 18 800 (18.9) 49 844 (50.2) <0.0001
Twins/triplets 3665 (3.6) 779 (21.3) 205 (5.6) 755 (20.6) 1926 (52.6)
Data are shown as n (%). MBRN indicates Medical Birth Registry of Norway; MoBa, Norwegian Mother and Child Cohort Study.
*No folic acid use (no/other supplements, no folic acid) vs folic acid use (folic acid only/folic acid plus other supplements) 4 weeks before to 8 weeks after gestation (combining 4 to 0,
0–4, and 5–8 weeks).
†Numbers from MBRN.
§Diabetes mellitus type 1 or type 2 before pregnancy, registered in MoBa and/or MBRN.
kAlcohol intake 3 months before pregnancy.
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designed with individual-level information of maternal folic acid
supplement use and infant risk of heart defect. Although several
studies have individual-level information of folic acid intake,
these studies have conﬂicting ﬁndings most likely related to
different design, bias, or confounding, they could also be
explained by regional differences in dietary vitamin insufﬁ-
ciency. A detailed discussion of previous reports in the context
of regions—for example, the United States,7,15,16,40–42 Hun-
gary,11,43 Western Australia,14 the Netherlands,8,13 China,12
and Norway17—can be found in Data S1.
To summarize previous ﬁndings from studies of the asso-
ciation between folic acid and congenital heart defects, we
found 1 randomized controlled trial reporting a nonsigniﬁcant
protective effect of high-dose folic acid supplements,11
whereas 1 cohort study17 and most other case–control
studies7,13–16,40,42 except one of the Dutch studies8 do not
support the hypothesis that folic acid supplementation
prevents congenital heart defects. The overall lack of a
protective effect from folic acid supplementation for heart
defect risk in previous studies supports the null ﬁndings in the
present study and is in stark contrast to inference drawn from
trend studies of birth defects, including heart defects, before-
and-after folic acid fortiﬁcation, or folic acid recommendation to
fertile women.38,44
In support of the null ﬁndings in the present birth cohort
study from Norway and Denmark, in particular for conotruncal
defects, is a report using a Mendelian randomization approach
that genotyped >3000 individuals with conotruncal defects
for the variants in the MTHFR (methylenetetrahydrofolate
reductase) gene.45 The variant 677TT has previously been
found to be associated with reduced folate levels in blood and
could be associated with offspring risk of heart defects. The
multicenter study found no association between the variant
677TT and the risk of conotruncal defects compared with
healthy controls. The authors also performed a meta-analysis
of 16 published studies on the relationship between
conotruncal heart defects and the variant 677TT and found
a weak positive association, likely explained by publication
bias: namely, that the studies with nonsigniﬁcant or null
associations are less frequently published.
Interpretation of the Null Association Between
Periconceptional Folic Acid and Cardiac Defects
There could be several explanations for the null ﬁndings
between maternal folic acid intake in the periconceptional
period and offspring risk of cardiac malformations in this study.
First, the ofﬁcially recommended folic acid dose of 0.4 mg/d
could be insufﬁcient to prevent cardiac malformations. The
feature of the 2 studies from Hungary,11,43 although of less
optimal design, was the use of high-dose folic acid (0.8 and
5.6 mg/d), which was associated with reduced risk of cardiac
malformation. Second, the null ﬁndings in the present study
could also be explained by sufﬁcient prepregnancy folate status
among the participating mothers. In less advantaged regions or
countries with lower baseline folate levels among fertile
women, folic acid supplementation could be beneﬁcial for the
prevention of cardiac defects, as has been suggested in parts of
China.12 Third, mothers who take folic acid supplements are in
general healthier than nonusers, indicated by lower body mass
index, less smoking, more pregnancy planning, higher age at
delivery, lower parity, or higher education,32 with some of these
factors also reported to be associated with lower offspring risk
of cardiac malformation. However, we were able to adjust for
potentially negative confounding. Fourth, the timing when
women start taking folic acid may be too late in the
periconceptional period to prevent development of cardiac
malformations. However, initiation of folic acid classiﬁed in
4-week intervals in the period 4 weeks before through 11 to
Table 3. Numbers and Birth Prevalence of Congenital Heart
Defects Among 94 228 Births in the DNBC, 1996–2003, and
Among 102 985 Births in MoBa, Norway, 2000–2009
Denmark (n=94 228) Norway (n=102 985)
n n/10 000 n n/10 000
Any heart defect 1077 114 1434 139
Any heart defect
without preterm PDA
995 106 1252 122
Heterotaxia 16 1.7 13 1.3
Conotruncal defect 105 11 96 9.3
AVSD 34 3.6 27 2.6
APVR 8 0.8 12 1.2
LVOTO 96 10 84 8.2
RVOTO 43 4.6 48 4.7
Septal defect, isolated 445 47 746 72
VSD 235 25 586 60
ASD 141 15 138 13
VSD+ASD 34 3.6 12 1.2
Unspecified septal defect 35 3.7 10 1.0
Other complex defects 1 0.1 0
Isolated PDA* 155 16 279 27
At-term gestation 73 7.7 97 9.4
Preterm gestation 82 8.7 182 18
Other specified defects 87 9.2 91 8.8
Unspecified cardiac defects 87 9.2 38 3.7
APVR indicates anomalous pulmonary venous return; ASD, atrial septal defect; AVSD,
atrioventricular septal defect; DNBC, Danish National Birth Cohort; LVOTO, left ventricle
outﬂow tract obstruction; MoBa, Norwegian Mother and Child Cohort Study; PDA, patent
ductus arteriosus; RVOTO, right ventricle outﬂow tract obstruction; VSD, ventricular
septal defect.
*Isolated PDA in preterm infants (gestational age <37 weeks) was not included in the
regression analyses.
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12 weeks after conception all showed a null association with
offspring risk of cardiac malformation. Fifth, it could be that
folic acid supplements prevent neural tube defects5,6 but not
cardiac malformations. Maternal folate insufﬁciency may act
differently during different time windows in embryonic organ
development; folate insufﬁciency probably disturbs neural tube
closure corresponding to an early period in embryo formation
but not formation of the later embryonic heart development
corresponding to a somewhat later period. Sixth, there could be
nondifferential misclassiﬁcation or measurement error of folic
acid exposure and timing, which may bias the estimate to the
null value. Interestingly, we found similar nonsigniﬁcant
country-speciﬁc relative risks despite differences in collection
and classiﬁcation of folic acid intake.
Although most likely not harmful,46,47 the effect of maternal
folic acid supplementation with respect to preventing cardiac
birth defects may be questioned, at least in regions with
sufﬁcient intake of dietary folate.
Study Strengths and Limitations
The use of prospectively collected information on individual-
level folic acid intake in early pregnancy precluded recall bias of
exposure. We have complete follow-up of all births (except for
204 mothers who gave birth abroad) through the nationwide
Medical Birth Registers. Before the analyses, we used an
established method for classifying folic acid exposure by type
(folic acid plus other supplements, only folic acid, non–folic
supplements, no supplements) in the period from 4 weeks
before through 8 weeks after conception and by timing
(initiation of supplement use) in the period from 4 weeks
before through 11 to 12 weeks after conception,34,35
Table 4. Relative Risk of Congenital Heart Defect* (Overall), Severe Heart Defect†, Conotruncal Defect,‡ and Septal Defect§ by
Maternal Intake of Folic Acid Supplements in the Periconceptional Period, Combining 94 228 Births in the DNBC, Denmark, 1996–
2003, and 102 985 Births in MoBa, Norway 1999–2009
Total Births,
N=186 861k
Any Congenital Heart
Defect,*n=2130
Severe Heart Defect,†
n=551
Conotruncal Heart Defect,‡
n=187
Septal Defect,§
n=1139
n (%) n
Adjusted RR¶
(95% CI) n
Adjusted RR¶
(95% CI) n
Adjusted RR¶
(95% CI) n
Adjusted RR¶
(95% CI)
Supplement use (4 wk before to 8 wk after conception)
None 52 401 (28.0) 569 1 Reference 157 1 Reference 55 1 Reference 296 1 Reference
Other supplements,
no folic acid
9414 (5.0) 104 0.99 0.80–1.22 25 0.92 0.61–1.41 8 0.84 0.40–1.77 61 1.06 0.80–1.39
Folic acid only 22 695 (12.2) 279 1.08 0.93–1.25 68 1.10 0.82–1.48 22 0.98 0.59–1.64 155 1.03 0.84–1.26
Folic acid plus
other supplementation
102 351
(54.8)
1178 1.07 0.97–1.19 301 1.02 0.84–1.25 102 0.93 0.66–1.31 627 1.06 0.92–1.22
Initiation of folic acid# (4 wk before to 12 wk after conception)
None 53 142 (28.4) 577 1 Reference 158 1 Reference 57 1 Reference 301 1 Reference
Weeks 4 to 1 62 924 (33.7) 753 1.11 1.00–1.25 192 1.08 0.87–1.34 65 0.95 0.66–1.38 397 1.08 0.92–1.26
Weeks 0–4 28 961 (15.5) 348 1.09 0.95–1.25 82 1.01 0.77–1.33 29 0.93 0.59–1.48 199 1.11 0.92–1.33
Weeks 5–8 33 161 (17.8) 356 0.98 0.86–1.12 95 1.00 0.77–1.30 30 0.85 0.54–1.33 186 0.93 0.77–1.11
Weeks 9–12** 8673 (4.6) 96 0.97 0.78–1.20 24 0.97 0.63–1.50 6 0.68 0.29–1.58 56 1.00 0.75–1.32
APVR indicates anomalous pulmonary venous return; ASD, atrial septal defect; AVSD, atrioventricular septal defect; DNBC, Danish National Birth Cohort; LVOTO, left ventricle outﬂow tract
obstruction; MoBa, Norwegian Mother and Child Cohort Study; PDA, patent ductus arteriosus; RR, risk ratio; RVOTO, right ventricle outﬂow tract obstruction; VSD, ventricular septal defect.
*Congenital heart defects: Heterotaxia, conotruncal defects, AVSD, APVR, LVOTO, RVOTO, VSD, ASD, VSD plus ASD, complex defects; patent ductus arteriosus (PDA) in live births at term
(gestational age ≥37 weeks); other speciﬁed heart defects; unspeciﬁed heart defects.
†Severe heart defects: heterotaxia, conotruncal defects (see below), AVSD, APVR, LVOTO, RVOTO, complex defects.
‡Conotruncal defects: truncus arteriosus, transposition of the great arteries, tetralogy of Fallot, pulmonary atresia with ventricular septal defect (tetralogy of Fallot type), double-outlet right
ventricle, conoventricular septal defect, interrupted aortic arch type B or C, supravalvular aortic stenosis, aortopulmonary window.
§Septal defects: VSD, ASD, VSD plus ASD.
kIndividuals with missing values of covariates were excluded in the adjusted analyses (total births n=10 352 [5.2% of 197 213]; any heart defect n=117 [5.2% of 2247]; severe defects
n=32; conotruncal defects n=14; septal defects n=52); see country-speciﬁc numbers in Tables S2 and S3.
¶Relative risk with 95% CI comparing supplement use with no use (reference) 4 weeks before to 8 weeks after conception (upper panel) or comparing initiation of folic acid supplements
with no use or non–folic acid supplements (reference) 4 weeks before to 12 weeks after conception (lower panel). RRs adjusted for interaction between country (Denmark/Norway) and
the following factors: year of birth (Denmark: 1996–1997, 1998, 1999, 2000, 2001, 2002–2003; Norway: 1999–2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008–2009),
maternal age (≤24, 25–29, 30–34, ≥35 years), birth order (ﬁrst, second, third or higher), maternal body mass index (<20, 20–24, 25–29, 30–34, ≥35), maternal heart defect (yes/no),
maternal epilepsy before pregnancy (yes/no). Categories for adjustment variables combined for severe and conotruncal defects.
#The 4 exposure categories in supplement use collapsed into no/yes; no is no folic acid use (no supplements and other supplements, no folic acid), and yes is folic acid use (folic acid only
and folic acid plus other supplementation.
**In DNBC, including week 11.
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corresponding to fetal cardiac development (third to eighth
weeks after conception). Folic acid is a well-characterized
exposure in the 2 cohorts27,28,48 and is found to mirror blood
plasma folate.49 We did not have information on perigestational
dietary folate, but from previous studies, supplemental folic
acid outweighs dietary folate, as women reporting folic acid
supplement use have higher plasma folate levels than nonusers
regardless of dietary intake.32
Low ascertainment of severe heart defects, including
conotruncal defects, is unlikely because these defects almost
always come to medical attention, either because of the need
for surgery or at death. In Denmark there is good agreement
between severe heart defect diagnoses in the NPR compared
with hospital records,24 and in Norway, nationwide health
registries and databases, as well as a clinical register, were
combined to ensure virtually complete ascertainment of all
heart defects among live births, stillbirths, and terminated
pregnancies, including information on chromosomal aberra-
tions and familial heart defect cases. All cases from the
clinical register at Oslo University Hospital have been coded
by senior pediatric cardiologists.
By combining country-speciﬁc ﬁndings in 2 national birth
cohorts, our study cohort was of sufﬁcient size to produce
narrow CIs, although we could not estimate RRs for the very
rare outcomes of severe defects. A large set of potential
confounders were available for evaluation, for adjustment or
restriction of the study population for sensitivity analyses.
Finally, although exposure data were collected somewhat
differently in the 2 cohorts, we decided not to harmonize
exposure among the 2 birth cohorts.50 The combined country-
speciﬁc estimates with corresponding country-speciﬁc con-
founders illustrate that despite the variation in exposure
collection and country-speciﬁc birth prevalence of heart defect,
we found no signiﬁcant association betweenmaternal folic acid
supplementation and heart defect risk in either birth cohort.
In conclusion, maternal periconceptional use of folic acid
supplements was not associated with offspring risk of congen-
ital heart defects, including conotruncal defects or other severe
defects, as well as septal defects, after combining 2 national
birth cohorts with prospectively collected information of
periconceptional supplement intake. The possible effect of
maternal folic acid supplementation with respect to preventing
cardiac birth defects may be questioned, at least in regions with
sufﬁcient intake of dietary folate.
Acknowledgments
Tatiana Fomina, PhD, Department of Global Health and Primary Care,
University of Bergen, Norway, programmed the algorithm that maps
congenital heart defects into embryologically related defect pheno-
types. Tomislav Dimoski, the Norwegian Knowledge Center for Health
services, Oslo, Norway, developed software necessary for obtaining
data from Norwegian hospitals, conducting the data collection, and
quality assurance of data. Dr Petter Hagemo constructed and
maintained the clinical database for congenital heart defects at the
Oslo University Hospital, Norway. Christine Roth, PhD, shared
valuable information on folic acid exposure collected in MoBa
(Norwegian Mother and Child Cohort Study). We are grateful to all
families in Denmark and Norway who participate in this ongoing
cohort study.
Sources of Funding
Dr Øyen was funded by grants from Lundbeck Foundation
(R48-A4793), Copenhagen, Denmark; Western Norway Regio-
nal Health Authorities (911734); Research Council Norway
(190858/V50), and University of Bergen (Smaforsk), Norway.
Dr Olsen was funded by Innovation Fund Denmark (grant no
09-06124, “Centre for Fetal Programming”). The DNBC
(Danish National Birth Cohort) was established with a
signiﬁcant grant from the Danish National Research Founda-
tion. Additional support was obtained from the Danish
Regional Committees, the Pharmacy Foundation, the Egmont
Foundation, the March of Dimes Birth Defects Foundation, the
Health Foundation, and other minor grants. MoBa (Norwegian
Mother and Child Cohort Study) is supported by the
Norwegian Ministry of Health and Care Services and the
Ministry of Education and Research and the US National
Institutes of Health, National Institute of Neurological Disor-
ders and Stroke (grant no. 1 UO1 NS 047537-01 and grant
no. 2 UO1 NS 047537-06A1).
Disclosures
None.
References
1. Jenkins KJ, Correa A, Feinstein JA, Botto LD, Britt AE, Daniels SR, Elixson M,
Warnes CA, Webb CL. Non-inherited risk factors and congenital cardiovas-
cular defects: current knowlegde: a scientiﬁc statement from the American
Heart Association Council on Cardiocascular Disease in the Young:
endorsed by the American Academy of Pediatrics. Circulation.
2007;115:2995–3014.
2. Pierpont ME, Basson CT, Benson DW, Gelb BD, Giglia TM, Goldmuntz E, McGee
G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart
defects: current knowledge: a scientiﬁc statement from the American Heart
Association Congenital Cardiac Defects Committee, Council on Cardiovascular
Disease in the Young: endorsed by the American Academy of Pediatrics.
Circulation. 2007;115:3015–3038.
3. Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart
disease: the glass half empty. Circ Res. 2013;112:707–720.
4. Øyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PKA, Melbye M. Recurrence
of congenital heart defects in families. Circulation. 2009;120:295–301.
5. Group MVSR. Prevention of neural tube defects. Results of the Medical
Research Council Vitamin Study. Lancet. 1991;338:131–137.
6. Czeizel A, Dudas I. Prevention of the ﬁrst occurence of neural tube defects by
periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832–
1835.
7. Shaw GM, O’Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal
periconeptional use of multivitamins and reduced risk for conotruncal heart
defects and limb deﬁciencies among offspring. Am J Med Genet.
1995;59:536–545.
8. van Beynum IM, Kapusta L, Bakker MK, den Heijer M, Blom HJ, de Walle HE.
Protective effect of periconceptional folic acid supplements on the risk of
DOI: 10.1161/JAHA.118.011615 Journal of the American Heart Association 11
Folic Acid in Pregnancy and Infant Heart Defects Øyen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on July 11, 2019
congenital heart defects: a registry-based case-control study in the northern
Netherlands. Eur Heart J. 2010;31:464–471.
9. Tang LS, Wlodarcyk BJ, Santillano DR, Miranda RC, Finell RH. Developmental
consequences of abnormal folate transport during murin heart morphogenesis.
Birth Defects Res A Clin Mol Teratol. 2004;70:449–458.
10. Van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M,
Daniels O, Blom HJ. Maternal MTHFR 677C>T is a risk factor for congenital
heart defects: effect modiﬁcaition by periconceptional folate supplementation.
Eur Heart J. 2009;27:981–987.
11. Czeizel AE. Prevention of congenital abnormalities by periconceptional
multivitamin supplementation. BMJ. 1993;306:1645–1648.
12. Li X, Li S, Mu D, Liu Z, Li Y, Lin Y, Chen X, You F, Li N, Deng K, Deng Y, Wang Y,
Zhu J. The association between periconceptional folic acid supplementation
and congenital heart defects: a case-control study in China. Prev Med.
2013;56:385–389.
13. Obermann-Borst SA, Isaacs A, Younes Z, van Schaik RH, van der Heiden IP,
van Duyn CM, Steegers EA, Steegers-Theunissen RP. General maternal
medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a
child with a congenital heart defect. Am J Obstet Gynecol. 2011;204:236.
e1–8.
14. Bower C, Miller M, Payne J, Serna P. Folate intake and the primary prevention
of non-neural birth defects. Aust N Z J Public Health. 2006;30:258–261.
15. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin
supplementation and risk of birth defects. Am J Epidemiol. 1999;150:675–682.
16. Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury
MJ, Willett WC. Preconceptional folate intak and malformations of the cardiac
outﬂow tract. Baltimore-Washington Infant Study Group. Epidemiology.
1998;9:95–98.
17. Leirgul E, Gildestad T, Nilsen RM, Fomina T, Brodwall K, Greve G, Vollset SE,
Holmstrøm H, Tell GS, Øyen N. Periconceptional folic acid supplementation
and infant risk of congenital heart defects in Norway 1999–2009. Paediatr
Perinat Epidemiol. 2015;29:391–400.
18. Bell KN, Oakley GP. Update on prevention of folic acid-preventable spina biﬁda
and anencephaly. Birth Defects Res A Clin Mol Teratol. 2009;85:102–107.
19. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for
congenital anomalies other than neural tube defects. Am J Med Genet C Semin
Med Genet. 2004;125C:12–21.
20. Wen SW, Liu S, Joseph KS, Rouleau J, Allen A. Pattern of infant mortality
caused by major congenital anomalies. Teratology. 2000;61:342–346.
21. Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, Andersen AM, Taxbol D,
Hansen KD, Juhl M, Schow TB, Sørensen HT, Andresen J, Mortensen EL, Olesen
AW, Søndergaard C. The Danish National Birth Cohort—its background,
structure and aim. Scand J Public Health. 2001;29:300–307.
22. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M,
Haugen M, Høiseth G, Knudsen GP, Paltiel L, Schreuder P, Tambs K, Vold L,
Stoltenberg C. Cohort proﬁle update: the Norwegian Mother and Child Cohort
Study (MoBa). Int J Epidemiol. 2016;45:382–388.
23. Øyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PKA, Melbye M. National
time trends in congenital heart defects, Denmark, 1977–2005. Am Heart J.
2009;157:467–473.
24. Agergaard P, Hebert A, Bjerre J, Sørensen KM, Olesen C, Østergaard JR.
Children diagnosed with congenital cardiac malformations at the national
university departments of pediatric cardiology: positive predictive values of
data in the Danish National Patient Registry. Clin Epidemiol. 2011;3:61–66.
25. Helweg-Larsen K. The Danish register of causes of death. Scand J Public
Health. 2011;39:26–29.
26. Leirgul E, Fomina T, Brodwall K, Greve G, Holmstrøm H, Vollset SE, Tell GS,
Øyen N. Birth prevalence of congenital heart defects in Norway 1994–2009—
a nationwide study. Am Heart J. 2014;168:956–964.
27. Strøm M, Granstrøm C, Lyall K, Ascherio A, Olsen SF. Research Letter: folic
acid supplementation and intake of folate in pregnancy in relation to offspring
risk of autism spectrum disorder. Psychol Med. 2018;48:1048–1054.
28. Nilsen RM, Vollset SE, Gjessing H, Magnus P, Meltzer HM, Haugen M, Ueland
PM. Patterns and predictors of folic acid supplement use among pregnant
women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr.
2006;84:1134–1141.
29. Olsen SF, Knudsen VK. Folic acid for the prevention of neural tube defects: the
Danish experience. Food Nutr Bull. 2008;29:S205–S209.
30. Olsen SF, Mikkelsen TB, Knudsen VK, Orozova-Bekkevold I, Halldorsson TI,
Strøm M, Østerdal ML. Data collected on maternal dietetary exposures in the
Danish National Birth Cohort. Paediatr Perinat Epidemiol. 2007;21:76–86.
31. Mikkelsen TB, Osler M, Olsen SF. Validity of protein, retinol, folic acid and n-3
fatty acid intakes estimated from the food-frequency questionnaire used in the
Danish National Birth Cohort. Public Health Nutr. 2006;9:771–778.
32. Roth C, Bjørke-Monsen AL, Reichborn-Kjennerud T, Nilsen RM, Smith GD,
Stoltenberg C, Suren P, Susser E, Ueland PM, Vollset SE, Magnus P. Use of
folic acid supplements in early pregnancy in relation to maternal plasma levels
in week 18 of pregnancy. Mol Nutr Food Res. 2013;57:653–660.
33. Kirby ML. Cardiac Development. Oxford, United Kingdom: Oxford University
Press; 2009.
34. Roth C, Magnus P, Schjolberg S, Stoltenberg C, Suren P, McKeague IW, Davey
Smith G, Reichborn-Kjennerud T, Susser E. Folic acid supplements in pregnancy
and severe language delay in children. JAMA. 2011;306:1566–1573.
35. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, Lie KK, Lipkin WI,
Magnus P, Reichborn-Kjennerud T, Schjolberg S, Davey Smith G, Øyen AS,
Susser E, Stoltenberg C. Association between maternal use of folic acid
supplements and risk of autism spectrum disorders in children. JAMA.
2013;309:570–577.
36. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A; National Birth Defects
Prevention Study. Seeking causes: classifying and evaluating congenital heart
defects in etiologic studies. Birth Defects Res A Clin Mol Teratol.
2007;79:714–727.
37. Olsen SF, Michaelsen KF, Rasmussen LB, Knudsen VK. Folsyre til kvinder, der
planlægger graviditet—kun fa følger anbefalingen! Copenhagen: Ernær-
ingsradet/Boje & Mobeck as; 2003.
38. Ionescu-Ittu R, Marelli AJ, Mackie AS, Pilote L. Prevalence of severe congenital
heart disease after folic acid fortiﬁcation of grain products: time trend analysis
in Quebec, Canada. BMJ. 2009;338:b1673.
39. Liu S, Joseph KS, Luo W, Leon JA, Lisonkova S, Van den Hof M, Evans J, Lim K,
Little J, Sauve R, Kramer MS; Canadian Perinatal Surveillance System (Public
Health Agency of Canada). Effect of folic acid food fortiﬁcation in Canada on
congenital heart disease subtypes. Circulation. 2016;134:647–655.
40. Correa A, Gilboa SM, Botto LD, Moore CA, Hobbs CA, Cleves MA, Riehle-
Colarusso TJ, Waller DK, Reece EA; National Birth Defects Prevention Study.
Lack of periconceptional vitamins or supplements that contain folic acid and
diabetes mellitus-associated birth defects. Am J Obstet Gynecol. 2012;
206:218.
41. Malik S, Cleves MA, Honein MA, Romitti PA, Botto LD, Yang S, Hobbs CA;
National Birth Defects Prevention S. Maternal smoking and congenital heart
defects. Pediatrics. 2008;121:e810–e816.
42. Shaw GM, Carmichael SL, Yang W, Lammer EJ. Periconceptional nutrient
intakes and risks of conotruncal heart defects. Birth Defects Res A Clin Mol
Teratol. 2010;88:144–151.
43. Csaky-Szunyogh M, Vereczkey A, Kosa Z, Gerencser B, Czeizel AE. Risk and
protective factors in the origin of conotruncal defects of heart—a population-
based case-control study. Am J Med Genet A. 2013;161A:2444–2452.
44. Khoshnood B, Loane M, Garne E, Addor MC, Arriola L, Bakker M, Barisic I,
Bianca S, Boyd P, Calzolari E, Doray B, Draper E, Gatt M, Haeusler M, Melve
KK, Latos-Bielenska A, McDonnell B, Mullaney C, Nelen V, O’Mahony M, Pierini
A, Queisser-Luft A, Randrianaivo H, Rankin J, Rissmann A, Salvador J, Tucker D,
Verellen-Dumoulin C, Wellesley D, Zymak-Zakutnya N, Dolk H. Recent
decrease in the prevalence of congenital heart defects in Europe. J Pediatr.
2013;162:108–113.e2.
45. Mamasoula C, Prentice RR, Pierscionek T, Pangilinan F, Mills JL, Druschel C,
Pass K, Russell MW, Hall D, T€opf A, Brown DL, Zelenika D, Bentham J,
Cosgrove C, Bhattacharya S, Riveron JG, Setchﬁeld K, Brook JD, Bu’Lock FA,
Thornborough C, Rahman TJ, Doza JP, Tan HL, O’Sullivan J, Stuart AG, Blue G,
Winlaw D, Postma AV, Mulder BJM, Zwinderman AH, van Engelen K, Moorman
AFM, Rauch A, Gewillig M, Breckpot J, Devriendt K, Lathrop GM, Farrall M,
Goodship JA, Cordell HJ, Brody LC, Keavney BD. Association between C677T
polymorphism of methylene tetrahydrofolate reductase and congenital heart
disease: meta-analysis of 7697 cases and 13 125 controls. Circ Cardiovasc
Genet. 2013;6:347–353.
46. Mortensen JH, Øyen N, Fomina T, Melbye M, Tretli S, Vollset SE, Bjørge T.
Supplemental folic acid in pregnancy and maternal cancer risk. Cancer
Epidemiol. 2015;39:805–811.
47. Mortensen JH, Øyen N, Fomina T, Melbye M, Tretli S, Vollset SE, Bjørge T.
Supplemental folic acid in pregnancy and childhood cancer risk. Br J Cancer.
2016;114:71–75.
48. Brantsaeter AL, Haugen M, Alexander J, Meltzer HM. Validity of a new food
frequency questionnaire for pregnant women in the Norwegian Mother and
Child Cohort Study (MoBa). Matern Child Nutr. 2008;4:28–43.
49. Bjørke-Monsen AL, Roth C, Magnus P, Midttun O, Nilsen RM, Reichborn-
Kjennerud T, Stoltenberg C, Susser E, Vollset SE, Ueland PM. Maternal B
vitamin status in pregnancy week 18 according to reported use of folic acid
supplements. Mol Nutr Food Res. 2013;57:645–652.
50. Tollanes MC, Strandberg-Larsen K, Forthun I, Petersen TG, Moster D, Andersen
AM, Stoltenberg C, Olsen J, Wilcox AJ. Cohort proﬁle: cerebral palsy in the
Norwegian and Danish birth cohorts (MOBAND-CP). BMJ Open. 2016;6:
e012777.
DOI: 10.1161/JAHA.118.011615 Journal of the American Heart Association 12
Folic Acid in Pregnancy and Infant Heart Defects Øyen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on July 11, 2019
SUPPLEMENTAL MATERIAL 
D
ow
nloaded from
 http://ahajournals.org by on July 11, 2019
 
 
Data S1. 
 
 
 
A detailed discussion on previous findings from studies of the association between 
folic acid and congenital heart defects 
 
From the United States, there are six case-control studies worth mentioning. From California, 1987-1998, 
mothers of 207 children with conotruncal heart defects and 481 randomly selected infants without 
malformations were telephone interviewed.1 There was a reduced risk of conotruncal heart defects in 
children of mothers who had taken multivitamins or folic acid fortified cereals (OR 0.70 95% CI 0.46-1.1), 
but with a  non-significant estimate. In a later study from California, 1999-2004, no preventive effect of 
multivitamins with folic acid on conotruncal defects was found, when comparing 186 infants with 
transposition of the great arteries or Tetralogy of Fallot (ToF) to 426 live controls.2 In the Slone 
Epidemiology Unit Birth Defects Study, 1993-1996, 101 infants with conotruncal defects, 86 ventricular 
septal defect (VSD), and 521 controls were recruited from hospitals in Boston, Philadelphia, and Toronto, 
Canada. No significant association were found between prenatal vitamins containing folic acid, and the 
types of heart defect.3 In the Baltimore-Washington Infant Study, 1987-1989, 126 non-syndromic outflow 
tract defects (53 transposition of the great arteries (TGA) and 73 other, e.g. ToF, double outlet right 
ventricle (DORV), truncus arteriosus (TA), supracristal VSD) were compared with 679 controls; the authors 
found no preventive effect of folic acid supplementations before pregnancy, a finding also supported by 
null findings for folic acid intake in the 5 weeks pregestational period, and for the lowest quartile of total 
folate intake.4  In a study from the US National Birth Defects Prevention Study, 1997-2002, with the 
intention to investigate the association between maternal smoking and offspring heart defect,5 the authors 
also reported the potential confounder maternal folic acid intake in the periconceptional period one month 
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before and 2 months after conception. By our calculation of the authors’ numbers (2284 exposed heart 
defect out of 3,067 all heart defects; 2,935 non-exposed controls out of 3947 controls), the unadjusted OR 
was 1.01 (95% CI 0.90-1.12), i.e. the association between folic acid and heart defect risk was null. In 
another report from the National Birth Defects Prevention Study, 1997-2004 (which might overlap with the 
study above), from Arkansas, California, Georgia (Atlanta), Iowa, Massachusetts, New Jersey (through 
2002), New York, North Carolina (beginning 2003), Texas, Utah (from 2003 onwards) on the joint effect of 
maternal diabetes and folic acid containing multivitamins on the risk of different types of heart defect in a 
multi-center study,6 we calculated an unadjusted OR of 0.95 (95% CI 0.85-1.06) of any heart defect for 
maternal use of multivitamins with folic acid (5,205 exposed with heart defects out of 5,979 individuals 
with heart defects; 4,737 exposed controls out of 5,408 controls).  
 
The Hungarian randomized controlled trial of neural tube defects,7 containing other defects as well, were 
extended with 8 months follow-up,8 and reported a reduced risk of heart defect, but the difference was 
non-significant comparing the group receiving multivitamin supplements containing high dose of 0.8 mg 
folic acid with the group receiving trace element supplements other than folic acid. The numbers were 
small, with only 10 exposed and 17 unexposed heart defect cases. In a later follow-up, but in case-control 
design, 598 children with heart defect born in Hungary 1980-1996 were compared to 902 matched 
controls,9 The authors reported a reduced risk of conotruncal heart defect in the group exposed to a very 
high dose of folic acid, on average 5.6 mg/d. 
 
In Western Australia, 1997-1998, with no folate fortification of staple food, there was no association 
between low dose folic acid (0.2 mg or more) and offspring heart defect risk comparing several birth defect 
outcomes, including 151 heart defects, to 578 live controls without birth defects, syndromes or 
chromosomal aberrations.10 
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Two recent Dutch case-control studies report from different areas. From the Northern Netherlands, 1996-
2005, including 611 children with heart defect identified within a birth defect registry, and two control 
groups; 2,401 supposedly non-folate related birth defects, and 3,343 births of women participating in 
previous cross-sectional studies, reported an adjusted ORs of 0.82 (95% CI 0.68-0.98) and 0.74 (95% CI 0.62-
0.88) of heart defect among offspring of women using periconceptional supplements with 0.4 mg/d folic 
acid comparing birth defect controls and live controls, respectively.11 However, from the Western 
Netherlands, 2003 onwards, the authors report a non-significant reduction of heart defect for folic acid 
intake of 0.4 mg or more (p=0.16), by our calculation, OR 0.79 (95% CI 0.57-1.10) when comparing 283 
heart defect (ToF, TGA, atrioventricular septal defect (AVSD), Coarctation of aorta, Aortic valve stenosis, 
pulmonary valve stenosis, Hypoplastic left heart syndrome) to 308 controls.12  
 
From China, a hospital-based case-control study with 358 prenatally identified heart defect and 422 
controls recruited consecutively among women receiving prenatal investigation in the provinces of 
Guangdong, Hubei, Fujian, and Shanxi, folic acid supplements reduced heart defect  risk by 65%.13 However, 
there may be limitations of the study, not discussed by the authors, such as design, selection into the study, 
and classification of exposure.  
 
In the recent study of around 520,000 births registered in the Medical Birth Registry of Norway, 1999-2009, 
with pre-birth registered use of folic acid and multivitamin supplements before pregnancy and during 
pregnancy,14 the authors identified 1,153 births with severe type of heart defect (heterotaxia, conotruncal 
defects, AVSD, anomalous pulmonary venous return (APVR), left or right ventricle outlet tract obstructions 
(LVOTO/RVOTO), other specified defects) and 3,280 with isolated septal defects (VSD, atrial septal defect 
(ASD), VSD+ASD). There was no significant association between intake of folic acid supplements (containing 
0.4 mg folic acid) and severe heart defect, but a surprising 20% increase of septal defects. 
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Table S1. The classification system for congenital heart defect phenotypes. 
 
Main groups  Detailed cardiac phenotypes 
Heterotaxia 
 
Situs inversus 
Isomerism 
Dextrocardia or levocardia with other heart defect 
Conotruncal defects Truncus arteriosus 
Transposition of the great arteries (TGA) 
Tetralogy of Fallot (ToF) 
Pulmonary atresia with ventricular septal defect (ToF type) 
Double outlet right ventricle (DORV) 
Conoventricular septal defect  
Interrupted aortic arch type B or C 
Supravalvular aortic stenosis 
Aortopulmonary window 
Atrioventricular septal defects Atrioventricular septal defects  
Anomalous pulmonary venous 
return (APVR) 
Total anomalous pulmonary venous return 
Partial anomalous pulmonary venous return 
Left Ventricular Outflow Tract 
Obstructions (LVOTO) 
Hypoplastic left heart syndrome (HLHS) 
Mitral valve stenosis 
Coarctation of the aorta (CoA) 
Interrupted aortic arch type A 
Valvular aortic stenosis 
Right Ventricular Outflow Tract 
Obstructions (RVOTO) 
 
Tricuspid atresia / stenosis 
Hypoplastic right heart syndrome (HRHS) 
Ebstein anomaly 
Valvular pulmonary atresia (not ToF anatomy) 
Arterial pulmonary atresia 
Valvular pulmonary stenosis 
Septal defects Atrial septal defects (ASD) 
Ventricular septal defects (VSD) 
ASD + VSD 
Otherwise specified or not specified septal defects  
Other complex cardiac defects Congenitally corrected transposition of the great arteries 
(ccTGA) 
Single ventricle (non-HLHS, non-HRHS) 
Double inlet left ventricle (DOLV) 
Absent PV  
Other cardiac defects Infundibular pulmonary stenosis 
Pulmonary insufficiency 
Subaortic stenosis 
Aortic insufficiency 
Mitral insufficiency 
Pulmonary arterial stenosis 
Cor triatriatum 
Coronary malformations 
Other specified malformation of the heart 
Unspecified malformations of the heart, great arteries, 
great veins 
Isolated Patent ductus arteriosus 
(PDA) 
Isolated patent ductus arteriosus (PDA) 
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Severe heart defects: Heterotaxia, Conotruncal defects, Atrioventricular septal defect, APVR, LVOTO, 
RVOTO (except valvular pulmonary stenosis), Other complex defects. 
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Table S2. Relative risk (RR) of congenital heart defect* (overall), severe heart defect†, conotruncal defect‡, and septal defect§ by maternal intake of folic 
acid supplements in the periconceptional period among 94,228 births The Danish National Birth Cohort (DNBC), Denmark, 1996-2003. 
 
Total no. 
of births 
(%)ǁ 
Any congenital heart defect* 
N=995 
Severe heart defect† 
N=303 
Conotruncal heart defect‡ 
N=105 
Septal defect§ 
N=445 
 
94,228 N 
No.  
per 
10,000 
Crude 
RR 
95% CI  
Adjusted  
RR# 
95% CI 
N 
No. 
per 
10,000 
Crude 
RR  
95% CI 
Adjusted  
RR# 
95% CI 
N 
 
No. 
per 
10,000 
Crude 
RR  
95% CI 
Adjusted  
RR#  
95% CI 
N 
 
No. 
per 
10,000 
Crude 
RR  
95% CI 
Adjusted  
RR# 
95% CI 
Supplement use  
(4 weeks before  
to 8 weeks 
after conception) 
                 
  None 
31,322 
(33.2) 
311 99 1  1  100 32 1  1  36 11 1  1 134 43 1 1 
  Other supplements,  
  no folic acid 
3,453 
(3.7) 
43 125 
1.25 
0.91-1.72 
1.35 
0.97-1.87 
9 26 
0.82  
0.41-1.62 
0.89 
0.45-1.76 
2 6 
0.50 
0.12-2.09 
0.53 
0.13-2.22 
26 75 
1.76 
1.16-2.67 
1.95 
1.27-3.01 
  Folic acid only 
3,889  
(4.1) 
36 93 
0.93  
0.66-1.31 
0.95 
0.67-1.35 
8 21 
0.65 
0.31-1.32 
0.63 
0.31-1.31 
4 10 
0.90 
0.32-2.52 
0.93 
0.33-2.64 
15 39 
0.90 
0.53-1.54 
0.94 
0.55-1.61 
  Folic acid plus other 
  supplementation 
55,564 
(59.0) 
605 109 
1.10  
0.96-1.26 
1.12 
0.97-1.30 
186 33 
1.05 
0.82-1.34 
1.01 
0.79-1.31 
63 11 
0.99 
0.66-1.49 
0.90 
0.58-1.38 
270 49 
1.14 
0.92-1.40 
1.14 
0.92-1.42 
Initiation of folic 
acid** (4 weeks 
before to 11 weeks  
after conception) 
                 
  None 32,252 
(34.9) 
323 100 1  1  101 31 1  1  38 12 1  1  142 44 1 1  
  Week -4 to -1 32,917 
(34.2) 
360 109 
1.09 
0.94-1.27 
1.13 
0.96-1.32 
106 32 
1.03 
0.78-1.35 
1.01 
0.75-1.36 
38 12 
0.98 
0.63-1.54 
0.89 
0.56-1.44 
161 49 
1.11 
0.89-1.39 
1.13 
0.89-1.43 
  Week 0 to 4 10,785 
(11.5) 
107 99 
0.99 
0.80-1.23 
0.98 
0.78-1.24 
31 29 
0.92 
0.61-1.37 
0.88 
0.57-1.36 
10 9 
0.79 
0.39-1.58 
0.63 
0.29-1.37 
47 44 
0.99 
0.71-1.38 
0.99 
0.70-1.39 
  Week 5 to 8 15,751 
(16.7) 
174 110 
1.10 
0.92-1.32 
1.08 
0.89-1.32 
57 36 
1.16 
0.84-1.60 
1.12 
0.78-1.61 
19 12 
1.02 
0.59-1.78 
0.99 
0.55-1.77 
77 49 
1.11 
0.84-1.47 
1.00 
0.74-1.35 
  Week 9 to 11 2,523 
(2.7) 
31 123 
1.23 
0.85-1.77 
1.16 
0.78-1.73 
8 32 
1.01 
0.50-2.15 
0.76 
0.31-2.08 
0    18 71 
1.62 
0.99-2.64 
1.45 
0.85-2.47 
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*†‡§ Congenital heart defects: see definitions in Table 4. 
ǁ The number of events includes the entire cohort, whereas in the adjusted analyses, individuals with missing values for covariates were excluded (total births n=7,556; any 
heart defect n=85; severe defect n=22, conotruncal defects n=10; septal defects n=36). 
# Relative risk (RR) with 95% confidence interval (CI) comparing supplement use with no use (reference) 4 weeks before to 8 weeks after conception (upper panel) or 
comparing initiation of folic acid supplements with no use/non-folic acid supplements (reference) 4 weeks before to 12 weeks after conception (lower panel). RRs adjusted 
for year of birth (1996-97, 1998, 1999, 2000, 2001, 2002-03), maternal age (≤24, 25-29, 30-34, ≥35 years), birth order (1, 2, 3+), maternal body mass index (<20, 20-24, 25-
29, 30-34, ≥35), maternal heart defect (yes/no), maternal epilepsy before pregnancy (yes/no). Categories for adjustment variables were combined for severe and 
conotruncal defects.  
** The four exposure categories in supplement use collapsed into no/yes; “no” is no folic acid use (no supplements and other supplements, no folic acid), and “yes” is folic 
acid use (folic acid only and folic acid plus other supplementation). 
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Table S3. Relative risk (RR) of congenital heart defect* (overall), severe heart defect†, conotruncal defect‡, and septal defect§ by maternal intake of folic 
acid supplements in the periconceptional period among 102,985 births in the Norwegian Mother and Child Cohort Study (MoBa), Norway, 1999-2009. 
 
 
 
 
Total no. 
of births 
(%)ǁ 
Any congenital heart defect* 
N=1,252 
Severe heart defect† 
N=280 
Conotruncal heart defect‡ 
N=96 
Septal defect§ 
N=746 
 
102,985 N 
No. 
per 
10,000 
Crude 
RR 
95% CI 
Adjusted  
RR#  
95% CI 
N 
No. 
per 
10,000 
Crude 
RR 
95% CI 
Adjusted  
RR#  
95% CI 
N 
 
No. 
per 
10,000 
Crude 
RR  
95% CI 
Adjusted  
RR# 
95% CI 
N 
 
No. 
per 
10,000 
Crude 
RR  
95% CI 
Adjusted  
RR#  
95% CI 
Supplement use  
(4 weeks before  
to 8 weeks  
after conception) 
   
  
            
  None 
25,229 
(24.5) 
312 124 1 1 70 28 1 1 23 9 1  1 184 73 1 1 
  Other supplements,  
  no folic acid 
6,431  
(6.2) 
65 101 
0.82 
0.63-1.07 
0.83 
0.64-1.09 
16 25 
0.90  
0.52-1.54 
0.97 
0.56-1.67 
6 9 
1.02 
0.42-2.51 
1.08 
0.43-2.67 
36 56 
0.77 
0.54-1.10 
0.77 
0.54-1.11 
  Folic acid only 
19,555 
(19.0) 
248 127 
1.03 
0.87-1.21 
1.07 
0.90-1.27 
62 32 
1.14  
0.81-1.61 
1.25 
0.87-1.79 
19 10 
1.07 
0.58-1.96 
1.07 
0.56-2.03 
142 73 
1.00 
0.80-1.24 
1.00 
0.80-1.25 
  Folic acid plus other 
  supplementation 
51,770 
(50.3) 
627 121 
0.98 
0.86-1.12 
1.02 
0.88-1.18 
132 25 
0.92  
0.69-1.23 
1.03 
0.75-1.42 
48 9 
1.02 
0.62-1.67 
1.00 
0.58-1.73 
384 74 
1.02 
0.85-1.21 
1.00 
0.83-1.21 
Initiation of folic 
acid** (4 weeks 
before to 12 weeks  
after conception) 
                 
  None 25,084 
(24.3) 
304 121 1 1 66 26 1 1 23 10 1 1 178 71 1 1 
  Week -4 to -1 32,827 
(31.9) 
417 127 
1.05 
0.91-1.21 
1.09 
0.93-1.28 
95 29 
1.10 
0.80-1.50 
1.25 
0.88-1.76 
32 10 
1.06 
0.62-1.82 
1.07 
0.59-1.93 
248 76 
1.06 
0.88-1.29 
1.04 
0.85-1.28 
  Week 0 to 5 19,471 
(18.9) 
254 130 
1.08 
0.91-1.27 
1.13 
0.95-1.35 
54 28 
1.05 
0.74-1.51 
1.19 
0.82-1.73 
21 11 
1.18 
0.65-2.13 
1.21 
0.65-2.27 
157 81 
1.14 
0.92-1.41 
1.13 
0.91-1.42 
  Week 5 to 8 19,027 
(18.5) 
204 107 
0.89 
0.74-1.06 
0.91 
0.76-1.09 
45 24 
0.90 
0.62-1.31 
0.91 
0.61-1.36 
14 7 
0.80 
0.41-1.56 
0.75 
0.37-1.51 
121 64 
0.90 
0.71-1.13 
0.88 
0.70-1-12 
  Week 9 to 12 6,576 
(6.4) 
73 111 
0.92 
0.71-1.18 
0.90 
0.70-1.17 
20 30 
1.15 
0.70-1.90 
1.08 
0.64-1.83 
6 9 
0.99 
0.40-2.44 
1.04 
0.42-2.59 
42 64 
0.90 
0.64-1.26 
0.88 
0.63-1.24 
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*†‡§ Congenital heart defects: see definitions in Table 4 
ǁ The number of events includes the entire cohort, whereas in the adjusted analyses, individuals with missing values for covariates were excluded (total 
births n=2,796; any heart defect n=32; severe defect n=10, conotruncal defects n=4; septal defects n=16). 
#  Relative risk (RR) with 95% confidence interval (CI) comparing supplement use with no use (reference) 4 weeks before to 8 weeks after conception (upper 
panel) or comparing initiation of folic acid supplements with no use/non-folic acid supplements (reference) 4 weeks before to 12 weeks after conception 
(lower panel). RRs adjusted for year of birth (1999-2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008-09), maternal age (years ≤24, 25-29, 30-34, ≥35), 
birth order (1, 2, 3+), maternal body mass index (<20, 20-24, 25-29, 30-34, ≥35), maternal heart defect (yes/no), maternal epilepsy before pregnancy 
(yes/no). Categories for adjustment variables combined for severe and conotruncal defects.  
** The four exposure categories in supplement use collapsed into no/yes; “no” is no folic acid use (no supplements and other supplements, no folic acid), 
and “yes” is folic acid use (folic acid only and folic acid plus other supplementation). 
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Table S4. Relative risks (RR) of congenital heart defect* ( overall), severe heart defect†, conotruncal defect‡, and septal defect§ by maternal intake of 
folic acid supplements, adjusting for covariates using three models, combining 94,228 birthsǁ in The Danish National Birth Cohort (DNBC), Denmark, 
1996-2003, and 102,985 birthsǁ in The Norwegian Mother and Child Cohort Study (MoBa), Norway, 1999-2009. 
 
*†‡§ Congenital heart defects: see definitions in Table 4. 
ǁ Individuals with missing values of covariates were excluded in the adjusted analyses, see numbers in Table 4 
 
 
 
Any congenital heart defect* Severe heart defect† Conotruncal defect‡ Septal defect§ 
 Adjusted RR# 
95% CI 
Adjusted RR# 
95% CI 
Adjusted RR# 
95% CI 
Adjusted RR# 
95% CI 
Model 1 
n=2,130 
Model 2 
n=2,037 
Model 3 
N=1,916 
Model 1 
n=551 
Model 2 
n=524 
Model 3 
n=497 
Model 1 
n=187 
Model 2 
n=180 
Model 3 
n=170 
Model 1 
n=1,139 
Model 2 
n=1,090 
Model 3 
n=1,025 
Supplement use  
(4 weeks before  
to 8 weeks after conception) 
            
   None 1 1 1 1 1 1 1 1 1 1 1 1 
   Other supplements,  
   no folic acid 
0.99 
0.80,1.22 
1.01 
0.82,1.24 
1.10 
0.89,1.38 
0.92 
0.61,1.41 
0.89 
0.57,1.38 
1.01 
0.64,1.58 
0.84 
0.40,1.77 
0.79 
0.36,1.75 
0.76 
0.32,1.78 
1.06 
0.80,1.39 
1.07 
0.81,1.42 
1.20 
0.89,1.60 
   Folic acid only 
1.08 
0.93,1.25 
1.12 
0.97,1.30 
1.15 
0.98,1.35 
1.10 
0.82,1.48 
1.09 
0.81,1.48 
1.21 
0.88,1.66 
0.98 
0.59,1.64 
1.00 
0.59,1.69 
1.13 
0.66,1.94 
1.03 
0.84,1.26 
1.05 
0.86,1.29 
1.07 
0.86,1.33 
   Folic acid plus other 
   supplementation 
1.07 
0.97,1.19 
1.06 
0.96,1.18 
1.10 
0.99,1.23 
1.02 
0.84,1.25 
0.99 
0.81,1.22 
1.02 
0.83,1.26 
0.93 
0.66,1.31 
0.88 
0.62,1.25 
0.93 
0.65,1.33 
1.06 
0.92,1.22 
1.07 
0.93,1.24 
1.11 
0.95,1.29 
Initiation of folic acid** 
(4 weeks before to 12 weeks 
after conception) 
   
   
  
 
  
 
   None 1 1 1 1 1 1 1 1 1 1 1 1 
   Week -4 to -1 1.11 
1.00,1.25 
1.13 
1.01,1.27 
1.15 
1.02,1.30 
1.08 
0.87,1.34 
1.06 
0.85,1.32 
1.11 
0.88,1.40 
0.95 
0.66,1.38 
0.93 
0.64,1.37 
0.99 
0.67,1.46 
1.08 
0.92,1.26 
1.10 
0.94,1.30 
1.13 
0.96,1.33 
   Week 0 to 4 1.09 
0.95,1.25 
1.08 
0.94,1.25 
1.08 
0.93,1.25 
1.01 
0.77,1.33 
0.97 
0.73,1.28 
0.98 
0.73,1.32 
0.93 
0.59,1.48 
0.82 
0.51,1.34 
0.91 
0.56,1.49 
1.11 
0.92,1.33 
1.10 
0.91,1.33 
1.10 
0.91,1.34 
   Week 5 to 8 0.98 
0.86,1.12 
0.98 
0.85,1.13 
1.00 
0.86,1.15 
1.00 
0.77,1.30 
0.99 
0.76,1.29 
1.00 
0.76,1.32 
0.85 
0.54,1.33 
0.82 
0.51,1.31 
0.91 
0.56,1.46 
0.93 
0.77,1.11 
0.93 
0.77,1.13 
0.95 
0.78,1.16 
   Week 9 to 12†† 0.97 
0.78,1.20 
0.97 
0.78,1.21 
1.00 
0.79,1.27 
0.97 
0.63,1.50 
0.93 
0.60,1.46 
1.02 
0.64,1.64 
0.68 
0.29,1.58 
0.62 
0.25,1.56 
0.72 
0.28,1.82 
1.00 
0.75,1.32 
0.99 
0.74,1.33 
1.02 
0.75,1.40 
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# Relative risk (RR) with 95% confidence interval (CI) comparing supplement use with no use (reference) 4 weeks before to 8 weeks after conception (upper 
panel) or comparing initiation of folic acid supplements with no use/non-folic acid supplements (reference) 4 weeks before to 12 weeks after conception 
(lower panel). Model 1: RRs adjusted for country, year of birth, maternal age (years <=24, 25-29, 30-34, >=35), birth order (1, 2, 3+), maternal epilepsy 
before conception (yes/no), maternal body mass index (BMI) (<20, 20-24, 25-29, 30-34, =<35), maternal heart defect (yes/no). Model 2: RRs adjusted for 
covariates as in Model 1, in addition, maternal socioeconomic status (Denmark: level 1, 2, 3, 5, 6, 7) and maternal education (Norway: years <12, 12, 13-16, 
>=17). Model 3: RRs adjusted for covariates as in Model 1, in addition, maternal pregestational diabetes (yes/no), maternal smoking before conception 
(daily, no), maternal alcohol consumption 3 months before conception (yes/no). 
** The four exposure categories in supplement use collapsed into no/yes; “no” is no folic acid use (no supplements and other supplements, no folic acid), 
and “yes” is folic acid use (folic acid only and folic acid plus other supplementation).   
††In DNBC, including week 11. 
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Table S5. Relative risk (RR) of congenital heart defects* (overall), by maternal intake of folic acid supplements in the periconceptional period, in   
sensitivity analyses with restrictions to live births, singleton births, mother without heart defect, or planned pregnancies, combining 94,228 births in The 
Danish National Birth Cohort (DNBC), Denmark, 1996-2003, and 102,985 births in The Norwegian Mother and Child Cohort Study (MoBa), Noway, 1999-
2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Any congenital heart defect: see definitions in Table 4.   
ǁ Individuals with missing values of covariates were excluded in the adjusted analyses (10,339 among 196,596 live births; 9,986 among 189,500 singletons; 
10,310 among 196,128 births of mothers without heart defect; 2,939 among 160,321 planned births).     
 
 
Live births 
N=186,257ǁ 
2,092 births with  
heart defect 
Singletons 
N=179,514ǁ 
1,957 infants with  
heart defect 
Mother without heart defect 
N=185,818ǁ 
2,104 infant with  
heart defect 
Planned pregnancy 
N=157,382ǁ 
1,797 infants with  
heart defect 
 
No. 
Adjusted RR# 
95% CI 
No.  
Adjusted RR# 
95% CI 
No. 
Adjusted  RR#  
95% CI 
No. 
Adjusted  RR#  
95% CI 
Supplement use  
(4 weeks before to 8 weeks after 
conception) 
            
    None 563 1 Reference 520 1 Reference 654 1 Reference 445 1 Reference 
    Other supplements,  
    no folic acid 103 1.00 0.81,1.23 95 0.99 0.80,1.23 104 1.00 0.81,1.23 86 1.06 0.85,1.34 
    Folic acid only 274 1.09 0.94,1.27 255 1.09 0.94,1.28 276 1.08 0.93,1.25 243 1.11 0.94,1.30 
    Folic acid plus other 
    supplementation 1,152 1.06 0.96,1.18 1,087 1.09 0.98,1.22 1,160 1.06 0.96,1.18 1,023 1.07 0.96,1.21 
Initiation of folic acid** 
(4 weeks before to 12 weeks after 
conception) 
            
    None 572 1 Reference 523 1 Reference 574 1 Reference 460 1 Reference 
    Week -4 to -1 738 1.11 0.99,1.24 682 1.13 1.01,1.27 740 1.10 0.98,1.23 706 1.10 0.98,1.24 
    Week 0 to 4 339 1.08 0.94,1.24 324 1.13 0.98,1.30 344 1.08 0.95,1.24 296 1.07 0.92,1.24 
    Week 5 to 8 349 0.97 0.85,1.11 336 1.01 0.88,1.16 352 0.97 0.85,1.11 264 0.95 0.82,1.11 
    Week 9 to 12†† 94 0.97 0.73,1.11  92 1.02 0.82,1.27 94 0.95 0.77,1.18 71 0.92 0.72,1.18 
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# Relative risk (RR) with 95% confidence interval (CI) comparing supplement use with no use (reference) 4 weeks before to 8 weeks after conception (upper 
panel) or comparing initiation of folic acid supplements with no use/non-folic acid supplements (reference) 4 weeks before to 12 weeks after conception 
(lower panel). RRs adjusted for country, year of birth, maternal age, birth order, maternal epilepsy, maternal BMI, maternal heart defect.  
** The four exposure categories in supplement use collapsed into no/yes; “no” is no folic acid use (no supplements and other supplements, no folic acid), 
and “yes” is folic acid use (folic acid only and folic acid plus other supplementation).  
†† In DNBC, including week 11. 
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